Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The company plans to expand its portfolio in regulated markets aggressively
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The first clinical trial is expected to commence in early 2022 both in Europe and the US
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Subscribe To Our Newsletter & Stay Updated
